Toxic oil syndrome T65.3

Tabuenca 1981

Acute phase: Women and men are affected equally often.

Chronic phase: Women are affected 6 to 10 times more often than men.

Acute phase: 7-10 days after consumption fever, dyspnea due to interstitial pneumonia and pulmonary edema, gastrointestinal complaints.

Subacute phase: After about 2 months, nonspecific pruriginous skin lesions, maculopapular or urticarial erythema, arthralgias, myalgias.

Chronic phase: From the 4th month, in 10-15% of patients neuromuscular syndrome with scleroderma-like or poikiloderma-like skin manifestations. Furthermore, livedo reticularis, Raynaud's syndrome, Sjögren's syndrome, carpal tunnel syndrome, dysphagia or pulmonary hypertension may occur.

eosinophilia (>1000 plates/mm3). IgE elevation. In 35-80% of cases ANA is positive.

Symptomatic physical and external therapy (see also scleroderma, progressive systemic), causal therapy unknown. If only sclerotic skin changes are present (without systemic involvement), phototherapy with UVA1 (20 ^J/cm2, for 6-8 weeks, 4 times/week) or PUVA bath therapy.

In case of systemic involvement, proceed as in progressive systemic scleroderma.

1. Bell S et al (1992) The toxic oil syndrome - an example of an exogenously induced autoimmune disease. dermatologist 43: 339-343
2. Sanchez-Porro Valades P et al (2003) Toxic oil syndrome: survival in the whole cohort between 1981 and 1995 J Clin Epidemiol 56: 701-708
3. Hubbard V et al (2003) Scleromyxoedema-like changes in four renal dialysis patients. Br J Dermatol 148: 563-568